No silver bullet for Covid-19, but rather a cocktail

COMMENT

It is a fable that silver bullets kill vampires. The creatures they kill are actually werewolves.

With the latest news about vaccines and variants, you would be excused for thinking this is a crazy out-of-control mess — and you would not be far wrong. But, we need to pull back from quick conclusions and try to understand what the best science is telling us.

At a time of great uncertainty, it is easy to latch on to any source of certainty — a silver bullet. For many, that vaccines are not a quick fix is a huge setback. Remember hydroxychloroquine? That was supposed to be a miracle cure. Now ivermectin claims that spot.

The one solid thing to take hold of is that we have some of the best science in the world right here in South Africa. We were among the first to learn about new variants (501Y.V2, also called B.1.351, was first identified in South Africa) and that is no accident — few countries do as much genetic sequencing as our labs do. The British, who take pride in being a leader in that field, were behind us in identifying more contagious variants.

Let’s take stock of where we are now — the setbacks, new promises, the need to be realistic.


Timing of the arrival of our first million doses of the Oxford-AstraZeneca vaccine from India could not have been much worse. They arrived just in time for the revelation that it offers scant protection against mild disease. It might protect against severe illness, based on the general observation that Covid-19 vaccines tend to do better in protecting against severe than mild illness.

Why?

Mild illness is prevented by antibodies. Antibody protection is a key driver of viral mutation because variants that escape being suppressed by antibodies have a competitive advantage over those that antibodies attack accurately. A virus’s survival strategy is replication, not killing the host, which is why endemic viruses tend to be less lethal than novel ones.

What of the batch of vaccines expiring in April? The Serum Institute of India could argue that there was urgency to the order, implying that it would be used expeditiously. It is not a big issue since the purpose was to get it out fast but nonetheless is a bit of a wake up call. The lesson: ask about expiry date when ordering.

What is to be done? The key missing data is protection against severe illness. So there is a case to continue roll-out while carefully monitoring results for efficacy against severe illness.

The South African government is, however, exploring options like sending this batch on to countries where it is effective and has negotiated with Johnson & Johnson to move delivery of their vaccine forward, which reduces the urgency of deploying the Oxford-AstraZeneca vaccine here.

In a key announcement this week, Health Minister Zweli Mkhize said Aspen Pharmacare’s Port Elizabeth factory will supply the Johnson & Johnson vaccine here from March.

The good news is that novel vaccine platforms developed over the past decade can be adapted relatively fast to new variants. The Oxford-AstraZeneca team predict that they will have a new version available in “autumn” (spring in the southern hemisphere).

In the meantime, we can start deploying other vaccines that have shown more efficacy against our local variant.

So what are our other options?

We already know about masking, distancing, hygiene, ventilation and, when all else fails, lockdowns. But what about other medications?

Steroid drug dexamethasone was found in June 2020 to significantly reduce deaths. The United Kingdom’s NHS also now recommends sarilumab and tocilizumab for severe cases. Another anti-inflammatory, colchicine (used to treat gout), has shown promise but with mixed reviews.

Just this week, Nature has published a promising lab-based study of flu medication molnupiravir (also called EIDD-2801 or MK-4482); large-scale clinical trials are due to complete in May.

Back to ivermectin. Why is the evidence taking so long to win over regulators? Don’t a lot of small studies add up to as much evidence as a big study? South Africa’s National Essential Medicine List (NEMLC) Covid-19 subcommittee has published a number of studies of evidence.

Trials reviewed so far are of low quality with potential for bias. One example, as pointed out by the NEMLC, is publication bias. If you went to all the trouble to conduct a large trial, you are likely to publish to justify the effort even if the result is negative; less so with a small study.
The number of trials where publication bias is the only concern is too small, however, to perform an authoritative analysis.

NEMLC’s bottom line: we do not know whether ivermectin is effective or not.
Over February, the International Ivermectin Project Team’s Dr Andrew Hill of the University of Liverpool is following a group of larger trials. Starting with a fixed group of trials and seeing them through to the end should eliminate publication bias. If they are well conducted that should eliminate other sources of bias.

In the meantime, what do we do? The latest surge has subsided, giving us some breathing space. We know how to suppress a surge even without medications. If ivermectin does prove to be effective, that will be great. But we need to stop looking for that elusive silver bullet. It isn’t vaccines or nothing. It isn’t ivermectin or nothing. It isn’t distancing or nothing. Until we get this thing beaten, we need a cocktail of measures that combine slowing transmission, reducing the odds of getting seriously ill and saving those who do get it badly.

Only when enough people have an effective vaccination will we really stop it. That could mean several rounds of vaccine to take into account new strains. The chances of new strains developing reduce if fewer people are infected at once — another reason to continue distancing and other non-pharmaceutical measures.

No silver bullet. It isn’t a werewolf.

Subscribe to the M&G

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years, and we’ve survived right from day one thanks to the support of readers who value fiercely independent journalism that is beholden to no-one. To help us continue for another 35 future years with the same proud values, please consider taking out a subscription.

Philip Machanick
Philip Machanick is an associate professor of computer science at Rhodes University

Related stories

Advertising

Subscribers only

Come what may, the UIF will pay

The fund – the main safety net for unemployed workers – will run at an almost R20-billion deficit

‘Terrorised’ family shines a light on traditional leadership for vulnerable...

The ambiguity between traditional and constitutional leadership has been exposed by the violent banishment of an Eastern Cape family

More top stories

Zondo commission: Molefe says Glencore sold Optimum to portray him...

Former Eskom chief executive paints himself as the victim of a plot at the hands of President Cyril Ramaphosa’s former business associates

Municipal workers convicted in R3.5m ‘Christmas cheer’ fund fraud scheme

A fund that was meant to provide much-needed, end-of-year cash for municipal workers was looted by the three signatories of the account

Tshiamiso Trust makes due on silicosis payout

Beneficiaries will now be able to apply to get money from the settlement almost two years after the Johannesburg high court ruled on the matter.

Shootings on Cape Flats claim 14 lives in less than...

At least 50 more police and other law enforcement officers were sent to the area in response to the spate of violence
Advertising

press releases

Loading latest Press Releases…